Review of the potential health impact of β-casomorphins and related peptides

Tabs

Article
doi
10.2903/j.efsa.2009.231r
European Food Safety Authority
Acknowledgement

This Scientific Report was prepared by DATEX with the cooperation of AMU. The European
Food Safety Authority wishes to thank the members of the DATEX Working Group on β-
casomorphins for the preparation of this Review:
Ivano De Noni, Richard J. FitzGerald, Hannu J. T. Korhonen, Yves Le Roux, Chris T.
Livesey, Inga Thorsdottir, Daniel Tomé, Renger Witkamp.

Type
Scientific Report of EFSA
Question Number
EFSA-Q-2008-379
Published
3 February 2009
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Article (968.89 KB)968.89 KB
Summary

EFSA has carried out a detailed review of the available scientific literature that addresses possible health effects of β-casomorphins and related peptides, and in particular β-casomorphin-7 (BCM7), a peptide sequence present in the milk protein β-casein. A few studies have suggested that BCM7 may contribute to increased risk of certain non-communicable diseases, such as autism, cardiovascular diseases and type I diabetes. EFSA undertook this work as part of its regular monitoring and assessment of possible emerging risks associated with the food chain.

Peptides are fragments of proteins that can be released during digestion of food or in some cases also during food processing. There have been claims of both health benefits and risks in relation to peptides.

EFSA decided to establish a Working Group in order to review the scientific literature on this subject and assess the need for EFSA to carry out a formal risk assessment.

Based on this review, EFSA concluded that a cause and effect relationship is not established between the dietary intake of BCM7, related peptides or their possible protein precursors and non-communicable diseases. Consequently, a formal EFSA risk assessment is not recommended.

Keywords
Review of the potential health impact of β-casomorphins and related peptides